UroGen Pharma Ltd. — Director's Dealing 2017

Nov 29, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2017-11-27

Reporting Person: ProQuest Investments IV, L.P. (10% Owner)
Reporting Person: ProQuest Associates IV LLC (10% Owner)
Reporting Person: Moorin Jay (10% Owner)
Reporting Person: SCHREIBER ALAIN (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-27	Ordinary Shares, par value NIS 0.01 per share	S	31491	$41.12	Disposed	1419838	Direct
2017-11-28	Ordinary Shares, par value NIS 0.01 per share	S	177807	$40.51	Disposed	1242031	Direct

Footnotes

F1: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares.

F2: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.

F3: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.